Alnylam Pharmaceuticals faced a significant downturn as market pressures weighed heavily on its stock performance.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) saw its stock price decline by 4.96% in yesterday's trading session, closing at CA$219.72. This drop comes amid broader market fluctuations and specific concerns regarding the company's future revenue potential.
Investor takeaway: Investors are advised to closely monitor Alnylam's performance and market conditions, particularly regarding demand for its products and the implications of recent analyst revisions.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$33.02B
P/E
44.2x
52W high
$495.55
52W low
$197.81
1W change
-7.38%
Beta
0.30
Analyst Price Targets
Based on 30 analysts covering ALNY · as of Oct 2, 2026
Wall Street analysts forecast ALNY stock price to rise 60.5% over the next 12 months.
Consensus
Buy4.23 / 5.00
Avg. Target
C$371.12
+60.5% Upside
Previously C$371.35 on Sep 17, 2026
Current Price
C$231.18
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
47.3%
Annualized
90-Day Vol
76.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$193.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$217.82 | C$185.04 – C$256.41 |
| 60 trading days | C$205.23 | C$162.96 – C$258.48 |
| 90 trading days | C$193.37 | C$145.78 – C$256.50 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
4.96% Decline
Alnylam's stock fell by nearly 5% yesterday, reflecting investor concerns over its revenue outlook.
Bull case
Alnylam has a strong lineup of RNA interference therapies that could boost future growth, especially if they gain more approvals and penetrate the market effectively.
Bear case
Recent downgrades from analysts regarding Amvuttra's demand assumptions have raised concerns about Alnylam's revenue growth, which could impact its position in the market.
Advertisement
Market Reaction to Analyst Downgrade
The drop in Alnylam's stock price was largely due to a downgrade by JPMorgan, which adjusted its price target based on new assumptions about Amvuttra's demand. This change in analyst sentiment has raised worries about the sustainability of Alnylam's revenue, especially given its reliance on a few key products.
Concerns Over Future Growth
Despite having a solid pipeline of RNAi therapies, the recent market reaction shows that investors are cautious about Alnylam's ability to sustain growth. The company's profit margin of 16.13% indicates some financial health, but pressures from pricing and demand uncertainties could hinder future performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
